Alembic Pharmaceuticals : Press Release January

For Immediate Release Q4 Net Revenue grew 18% to Rs 740 Crores, Net Profit at Rs 94 er Vadodara May 3rd,2017

Alembic Pharmaceuticals Limited reported itsconsolidated financialresults for the fourth quarter ending 31stMarch 2017.

Financial Highlights

• Net Sales for the quarter up 18% toRs 740 crores

• Net Profit forthe quarter at Rs 94 crores against Rs 92 crores last year.

• FY17 Net sales at Rs 3131 crores as against Rs 3162 crores last year.

  Mr. Pranav Amin, Managing Director, Alembic Pharmaceuticals Limited said"We have closed out very good year whereour facilities remain in compliance and wecontinue to investfor the future.We spent Rs 427 crore on R&D and filed20 ANDA applications. "

  Operational Highlights International Business

• International formulation business grew 44% to Rs 273 crores for the quarter

• US Business grew 54%toRs 200 croresfor thequarter

• Bioequivalence facility successfully audited by the US FDA without any observations

• 4 ANDA approvals receivedduring the year,Cumulative ANDA approvals at 52

• Highest ever 10 ANDA filings during the quarter and 20 ANDA filingsfor FY17

• Cumulative ANDA filingsat 95

• FY17 R&D spend at Rs 427 Crores, approximately 14%of Sales.

  India Formulations Business

• Indiaformulations business for the quarter at Rs 286 crores as against Rs 269 crores last year

• India formulations business for the year at Rs 1255 crores as against Rs 1176 crores last year

  ALEMBICPHARMACEUTICALS LIMITED

  REGO. OFFICE :ALEMBIC ROAD,VADODARA • 390 003. NDIA •TEL:[phone] •FAX :[phone]

  Website :www.alembic-india.com• E-mail :alembic@alemb c.co.in

  Dividend

• The Board has recommended dividend on equity shares at Rs 4.00per share

i.e.200% for 16-17 (P.Y. Rs 4.00 per sharei.e.200%)

Summary of Total Revenue i s as under:

(Rs in Crores)

Particulars	Q4 FY17	Q4 FY16	FY17	FY16
Formulation	273	190	1236	1461
International
India	286	269	1255	1176
API	181	167	640	525
Total	740	626	3131	3162

The Profit break-up i s as under:

(Rs in Crores)

Particulars	Q4 FY17	Q4 FY16	FY17	FY16
EBITDA Pre R&D	244	254	1029	1313
EB/TOA PreR&O%	33%	41%	33%	42%
EBITDA PostR&D	135	143	615	1007
EB/TOA Post R&O %	18%	23%	20%	32%
Profit Before Tax	112	120	529	936
Net Profit after Tax	94	92	401	720

About AlembicPharmaceuticals Limited

Alembic PharmaceuticalsLimited,a vertically integratedresearch and development pharmaceutical company,has been at the forefront of healthcare since 1907.

ALEMBIC PHARMACEUTICALS LIMITED

A!!! fi

Headquartered in India, Alembic is a publicly listed company that manufactures and markets generic pharmaceutical products all over the world. Alembic's state of the art research and manufacturing facilities are approved by regulatory authorities of many developed countries including the US FDA.Alembic is one ofthe leaders in branded generics in India.Alembic's brands,marketed through a marketing team of over 5000 are well recognized by doctors and patients.

Information about the company can be found at www.alembic-india .com;(reuters:ALEM. NS) (bloomberg :ALPM) (nse:APLLTD) (bse:533573)

For more information contact:

Ajay Kumar Desai Mitanshu Shah

Phone: [phone] Phone: [phone]

Email:[e-mail].i n Email:[e-mail].i n

ALEMBIC PHARMACEUTICALS LIMITED

REGO.OFFICE : ALEMB C ROAD, VADODARA - 390 003.INDIA •TEL :[phone] •FAX :[phone]

Website :www.alembic-india.com • E-mail:[e-mail]